Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection (Q24197858)

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Differential inhibition of reverse transcriptase and cellular DNA polymerase-alpha activities by lignans isolated from Chinese herbs, Phyllanthus myrtifolius Moon, and tannins from Lonicera japonica Thunb and Castanopsis hystrix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Vaccines for preventing hepatitis B in health-care workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Practical aspects in data monitoring: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Thymosin alpha 1: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Molecular phylogenetics of Phyllanthaceae inferred from five genes (plastid atpB, matK, 3'ndhF, rbcL, and nuclear PHYC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Comparative pharmacognostic studies of three Phyllanthus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Effectiveness of hepatitis B treatment in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Management of chronic hepatitis B: experience from China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

Phyllanthus species for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

From lab to bedside: emerging clinical applications of thymosin α1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009004.PUB2